{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Subject MM-82"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Subject MM-91"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Subject MM-92"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Subject MM-95"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Subject MM-96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Subject MM-98"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Subject MM-99"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Subject MM-109"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Subject M-111"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Key: 1 = very good partial response (VGPR); 2 = partial response (PR); 3 = minimal response (MR); 4 = stable disease (SD); 5 = progressive disease (PD). Please see IC50 and CI results in the other primary outcome measures.","groups":[{"description":"Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"14 months","title":"Best Overall Response, by Subject","type":"PRIMARY","unitOfMeasure":"IMWG Uniform Response Grade"}